Abstract
This paper tests whether the measured cost-effectiveness of treating different subgroups of an incident population of lung cancer patients differs significantly and, by implication, whether the provision of care to these patients is tolerably efficient in economic terms. Data from administrative records and Registry follow-up on 544 non-small cell lung cancer patients diagnosed at a single NCI-designated Comprehensive Cancer Center are used to conduct the empirical analysis. The main results show statistically significant differences in cumulative costs and patient outcomes across subgroups differing by disease stage and treatment modality. These findings imply that the delivery of lung cancer care is inefficient. Substantive and methodological implications are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. Power and J. Eisenberg, Are we ready to use cost-effectiveness analysis in health care decision-making? A health services research challenge for clinicians, patients, health care systems and public policy, Medical Care 36 (Suppl.) (1998) MS10–MS17.
Z. Khan, K. Rascati and J. Koeller, Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer, Pharmacoeconomics 16 (1999) 43–57.
J. Bailar and H. Gornick, Cancer undefeated, New England Journal of Medicine 336 (1997) 1569–1574.
C. Desch, B. Hillner and T. Smith, Economic considerations in the care of lung cancer patients, Current Opinion in Oncology 8 (1996) 126–132.
P. Goodwin and F. Shepherd, Economic issues in lung cancer: A review, Journal of Clinical Oncology 16 (1998) 3900–3912.
D. Mather, S. Sullivan and T. Parasuraman, Beyond survival: Economic analyses of chemotherapy in advanced, inoperable NSCLC, Oncology 2 (1998) 199–209.
J. Ruckdeschel, Is chemotherapy for metastatic nonsmall-cell lung cancer "worth it"? Journal of Clinical Oncology 8 (1990) 1293–1296.
J. Bailes, Cost aspects of palliative cancer care, Seminars in Oncology 22 (Suppl. 3) (1995) 64–66.
R. Greenlee, T. Murray, S. Bolden and P. Wingo, Cancer statistics 2000, CA Cancer Journal for Clinicians 50 (2000) 7–33.
W. Fry, J. Phillips and H. Menck, Ten-year survey of lung cancer treatment and survival in hospitals in the United States: A national cancer data base report, Cancer 86 (1999) 1867–1876.
B. Hillner, M. McDonald, C. Desch, T. Smith, L. Penberthy, P. Maddox et al., Costs of care associated with non-small-cell lung cancer in a commercially insured cohort, Journal of Clinical Oncology 16 (1998) 1420–1424.
L. Penberthy, S.M. Retchin, M.K. McDonald, D.K. McClish, C.E. Desch, G.F. Riley et al., Predictors of Medicare costs in elderly benefi-ciaries with breast, lung, or prostate cancer, Health Care Management Science 2 (1999) 149–160.
R. Kaplan, Quality of Life assessment for cost/utility studies in cancer, Cancer Treatment Reviews 19 (Suppl. A) (1993) 85–96.
G. Torrance, Measurement of health state utilities for economic appraisal: A review, Journal of Health Economics 5 (1986) 1–30.
C. Mountain, Revisions in the international system for staging lung cancer, Chest 111 (1997) 710–717.
P. Fenn, A. McGuire, M. Backhouse and D. Jones, Modelling programme costs in economic evaluation, Journal of Health Economics 15 (1996) 115–125.
M. Extermann, Measuring comorbidity in older cancer patients, European Journal of Cancer 36 (2000) 453–471.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chirikos, T.N. Appraising the Economic Efficiency of Cancer Treatment: An Exploratory Analysis of Lung Cancer. Health Care Management Science 6, 87–95 (2003). https://doi.org/10.1023/A:1023380918605
Issue Date:
DOI: https://doi.org/10.1023/A:1023380918605